Early diagnosis of COPD, chronic obstructive pulmonary disease, increases the quality of life of the patient and the efficacy ...
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a ...
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...
The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.
Afrin (oxymetazoline) and Flonase (fluticasone) are two common nasal sprays that work differently to help relieve nasal ...